Project: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes
| Acronym | SIGNAL (Reference Number: ERAPERMED2022-248) |
| Duration | 01/05/2023 - 30/04/2026 |
| Project Topic | Diabetes and the associated cardiovascular and renal complications are among the largest burdens for patients, and also the public healthcare system. In Europe 700.000 deaths are attributed to diabetes and associated complications yearly, with costs exceeding 200 bn €. Diabetic kidney disease reduces life expectancy up to 16 years. A number of different drugs that show a significant benefit are available, with the largest benefit produced if given at the earliest possible time point. However, guidance on which specific medication to apply per patient is currently lacking, as also evident based on clinical trials. Partners in this consortium have investigated urine proteome in multiple clinical studies and identified several biomarkers expected to predict drug response. In addition, the consortium has access to large biobanks of diabetic patients undergoing different types of pharmacological intervention, with available information on response. Building on these extensive available resources, SIGNAL targets to evaluate and establish predictive biomarkers that enable guiding anti-diabetic treatment with respect to prevention of chronic kidney and cardiovascular disease. This involves compilation of the available resources, data re-analysis for establishment of optimal biomarker profiles with predictive value for diabetic treatment response, followed by its independent validation, in parallel to the health economics assessment of the clinical implementation of these markers. The availability of clinical resources, datasets from thousands of individual patients, and well characterized analytical platforms together with the vast expertise of partners in the different study aspects ensures the establishment and prompt advancement towards clinical implementation of predictive biomarkers-opening the way towards the personalized treatment of diabetic patients. |
| Network | ERA PerMed |
| Call | 5th Joint Transnational Call for Proposals (2022) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Steno Diabetes Center Copenhagen (part of Region Hovedstaden) | Coordinator | Denmark |
| 2 | INSERM | Partner | France |
| 3 | San Pedro Hospital, Rioja Salud Foundation | Partner | Spain |
| 4 | Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz | Partner | Spain |
| 5 | Medical University Innsbruck | Partner | Austria |
| 6 | Mosaiques-diagnostics GmbH | Partner | Germany |